Evidence map›Paper›PMID 29872148›Full record

ArticleBritish journal of cancer2018

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study.

Simon Pernot, Olivier Dubreuil, Thomas Aparicio, Karine Le Malicot, David Tougeron, Céline Lepère, Cedric Lecaille, Lysiane Marthey, Juliette Palle, Jean-Baptiste Bachet and 2 more

Open access · hybridAbstract readClinical StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Diffuse gastric cancer: histologic, molecular, and genetic basis of disease.Translational gastroenterology and hepatology · 2020
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Regulation of Proliferation and Epithelial-to-Mesenchymal Transition (EMT) of Gastric Cancer by ZEB1 via Modulating Wnt5a and Related Mechanisms.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Simon PernotDepartment of GI Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.ORCID 0000-0003-4580-585X
Olivier DubreuilHôpital de la Pitié Salpétrière Hospital, Paris, France.
Thomas AparicioDepartment of Gastroenterology, Hôpital Saint-Louis, APHP, Paris Diderot University, Sorbonne Paris Cité, Paris, France.
Karine Le MalicotFédération Française de Cancérologie Digestive, Faculty of Medicine, Dijon, France.
David TougeronDepartment of Gastroenterology, Poiteirs University Hospital, Poitiers, France.
Céline LepèreDepartment of GI Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
Cedric LecailleDepartment of Gastroenterology and Digestive Oncology, Polyclinique de Bordeaux Nord, Bordeaux, France.
Lysiane MartheyHôpitaux Universitaires Paris Sud, Gastroenterology Unit, APHP, Paris-Sud University, Le Kremlin Bicêtre, France.
Juliette PalleDepartment of GI Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
Jean-Baptiste BachetHôpital de la Pitié Salpétrière Hospital, Paris, France.
Aziz ZaananDepartment of GI Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
Julien TaiebDepartment of GI Oncology, Hôpital Européen Georges-Pompidou, APHP, Paris Descartes University, Sorbonne Paris Cité, Paris, France. jtaieb75@gmail.com.
Université Paris Cité · FRSorbonne Université · FRDélégation Paris 5 · FRDélégation Paris 7 · FRFédération Francophone de Cancérologie Digestive · FRPolyclinique de Bordeaux-Tondu · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriplet chemotherapy, with docetaxel-5FU-oxaliplatin (TEFOX), has yielded promising results in patients with advanced and operable gastric adenocarcinoma. This may prove useful in treating signet ring cell carcinoma (SRCC), which is known to be chemoresistant and has a poor prognosis. We therefore evaluated TEFOX in patients with untreated advanced SRCC.

methodsPatients with metastatic or locally advanced non-resectable SRCC were treated with TEFOX. Chemotherapy was administered every 14 days, with combined docetaxel (50 mg/m

resultsAmong 65 patients enrolled, including 17 with linitis plastica, ORR and DCR were 66.1% and 87.6%, respectively. Median PFS and OS were 9.7 months (95% CI [6.9-11.4]) and 14.3 months (95% CI [11.6-21.6]) respectively. Twenty-six patients (40%) initially considered as unresectable had secondary resection (n = 24) or radiotherapy (n = 2) with curative intent, with median PFS and OS of 12.4 and 26.2 months, respectively.

conclusionsTEFOX appears to be effective as first-line treatment in advanced gastric SRCC and has an acceptable safety profile. It allowed a curative intent approach in 40% of patients. Considering the low chemosensitivity of SRCC reported with other chemotherapy regimens and pending for randomised studies, TEFOX might be an option in advanced gastric SRCC.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Signet Ring CellDocetaxelDrug Administration ScheduleFemaleHumansMaleMiddle AgedOxaliplatinStomach NeoplasmsSurvival AnalysisTreatment OutcomeYoung AdultDocetaxelOxaliplatin

Identifiers

PMID29872148
PMCPMC6133962
OpenAlexW2805244954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.